dyslipidaemia
Cardiovascular · 2006–2007
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nicotinic acid Treatment of dyslipidaemia with adequately controlled LDL-C and inadequately controlled HDL-C despite statin monotherapy, for use in combination with an HMG… | Mar 2007 | Recommended | no section in document |
| nicotinic acid Treatment of dyslipidaemia with adequately controlled LDL-C and inadequately controlled HDL-C despite statin monotherapy, as add-on therapy to an HMG CoA… | Mar 2007 | Recommended | no section in document |
| amlodipine besylate with atorvastatin calcium Fixed combination for patients with concomitant hypertension and/or angina and dyslipidaemia who meet criteria for lipid-lowering therapy. | Jul 2006 | Recommended with restriction | no section in document |
| rosuvastatin calcium Treatment of hypercholesterolaemia as an adjunct to diet when the response to diet and exercise is inadequate. | Jul 2006 | Recommended with restriction | no section in document |
What the PBS pays
$357M in government benefit over 2024–25, across 27,171,286 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| amlodipine besylate with atorvastatin calcium | $224.9M |
| rosuvastatin calcium | $132.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.